ArticleFrontiers in medicine2025
Progression characteristics of biliary atresia during the waiting period for liver transplantation: a single-center observational study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biliary atresia (BA) is a progressive, fibro-obliterative cholangiopathy of infancy that inevitably leads to cirrhosis and liver failure without intervention. While the rapid progression of BA is widely recognized, the precise dynamics of its natural history remain poorly quantified due to the confounding effects of surgical intervention. Aims: This study aimed to characterize the natural progression of BA cirrhosis by analyzing the trajectory of clinical, laboratory, and histological changes during the unique window between diagnostic confirmation by intraoperative cholangiography and subsequent liver transplantation in children who did not undergo Kasai portoenterostomy. Methods: In this single-center, observational study, we analyzed 153 children with cholangiography-confirmed BA who underwent living donor LT without primary Kasai portoenterostomy. The pathological progression of cholestatic cirrhosis and laboratory parameters such as hematological examination and liver function in children with hepatic cholestatic cirrhosis at the two time points were compared to find factors that can predict the progression of BA cirrhosis. Results: The cohort comprised 153 children with cholangiography-confirmed BA who underwent liver transplantation. The mean age at diagnosing BA was 78.64 ± 31.43 days. The mean interval from exploration to liver transplantation (disease progression time) was 83.36 ± 28.37 days. Within this short period, 77.12% (118/153) of children progressed to end-stage (Stage IV) cirrhosis. Longitudinal analysis revealed a significant increase in white blood cells (WBC, 3.09 ± 5.31 × 10 Conclusion: This study provides unprecedented quantification of the rapid natural progression of BA cirrhosis, revealing a critical 3 month window of clinical deterioration. The dynamic changes in routinely available laboratory markers, particularly neutrophil percentage and ammonia, offer clinically accessible indicators for risk stratification and monitoring, forming a practical "dashboard" for managing BA patients awaiting transplantation in resource-varied settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.